TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
Cytiva BioProcess R&D AB
Closing information (x1000 DKK)
Closing information | 2022/12 | 2021/12 | 2020/12 |
Turnover | 11,367,800 | 10,751,573 | 7,380,498 |
Financial expenses | 7,713 | 9,599 | 8,852 |
Earnings before taxes | 6,616,809 | 5,732,972 | 2,381,344 |
EBITDA | 11,016,209 | 10,524,964 | 7,264,861 |
Total assets | 23,662,667 | 19,308,990 | 30,735,025 |
Current assets | 8,801,979 | 179,418 | 6,361,703 |
Current liabilities | 15,288,255 | 9,775,869 | 644,036 |
Equity capital | 7,707,407 | 7,755,199 | 27,791,354 |
- share capital | 67 | 73 | 74 |
Employees (average) | 0 | 0 | 0 |
Financial ratios
Fiscal year | 2022/12 | 2021/12 | 2020/12 |
Solvency | 32.6% | 40.2% | 90.4% |
Turnover per employee | |||
Profit as a percentage of turnover | 58.2% | 53.3% | 32.3% |
Return on assets (ROA) | 28.0% | 29.7% | 7.8% |
Current ratio | 57.6% | 1.8% | 987.8% |
Return on equity (ROE) | 85.9% | 73.9% | 8.6% |
Change turnover | 1,487,111 | 3,510,779 | 2,347,912 |
Change turnover % | 15% | 48% | 47% |
Chg. No. of employees | 0 | 0 | 0 |
Chg. No. of employees % |
Total value of public sale
Fiscal year | 2022/12 | 2021/12 | 2020/12 |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.